Clinical trials: insulin glargine
Diabetes Mellitus, Type 1
Comparing Long-acting Insulins During Exercise in Type 1 Diabetes
Exercise is an important part of a healthy lifestyle, and many people with Type 1 Diabetes like to take part in regular sport and exercise.
- Trial name
- NCT01440439
- Testing
- Insulin glargine, Insulin detemir
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Buckinghamshire Healthcare NHS Trust
Diabetes Mellitus, Type 2
Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients
The study aims to evaluate the effects of Insulin Degludec/Liraglutide on glycemic variability assessed by continuous glycemic monitoring with the function time in range, serum markers of inflammation, markers of endothelial…
- Trial name
- NCT05360537
- Testing
- Insulin Degludec / Liraglutide Injectable Product, Insulin Glargine
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Palermo
Poor Glycemic Control
Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients
Most coronary artery bypass graft surgery (CABG) patients develop high blood sugar while they are in the hospital. No studies have shown what the best insulin regimen is for CABG patients with type 2 diabetes is after going home…
- Trial name
- CABG-D/C (NCT01792830)
- Testing
- Metformin, Glargine insulin, Glulisine
- Where
- 3 sites in United States
- Volunteers
- 175 people
- Sponsor
- Emory University
Diabetes Mellitus, Type 2, Obesity
A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes.
- Trial name
- NCT05514535
- Testing
- Semaglutide, Insuline glargine U100 (reduced), Insuline glargine U100 (titrated)
- Where
- 239 sites in United States, Czechia and 10 more
- Volunteers
- 573 people
- Sponsor
- Novo Nordisk A/S
Diabetes
Feasibility Study to Determine the Optimal Calibration Method for Glucose Sensors
Two new glucose sensors (IR-Glucose Reader (Joanneum Research, Austria), IR-CGM (IMM, Germany)) will be investigated to determine the optimal calibration method in patients with type 1 diabetes
- Trial name
- REACT4SENSOR (NCT02155023)
- Testing
- Insulin dosing, Glucose sensors IR-Glucose Reader (Joanneum Research, Austria), IR-CGM (IMM, Germany)
- Where
- Austria
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Diabetes
Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics
Over the past 40 years, new types of insulins have been marketed to mirror the effect of endogenous insulin. With the existing long-acting insulin product patents expiring and the FDA approval of new biosimilar and innovator…
- Trial name
- NCT02922179
- Testing
- Long- and intermediate- acting insulins
- Volunteers
- 103,951 people
- Sponsor
- Biologics & Biosimilars Collective Intelligence Consortium
Diabetes Mellitus, Type 2, Diabetic Complication
mHealth Titration and Management
The principal objective of this application is to improve glycemic control of diabetic patients treated with basal insulin through use of an innovative, FDA-cleared smartphone-based insulin titration application connected to…
- Trial name
- NCT03908762
- Testing
- iSage App with connected glucometer, Magnet
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Amalgam Rx, Inc.
Diabetes
Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients
Comparison of efficacy and safety of different insulin regimens between basal bolus and premixed insulin in poorly controlled type 2 diabetes
- Trial name
- COMPAR (NCT02219750)
- Testing
- switch twice-daily insulin
- Where
- Taiwan
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- Mackay Memorial Hospital
Diabetes Mellitus, Type 2
Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus
The purpose of this study is to show the non-inferiority of insulin glulisine administered with 1 meal versus 2 meals versus 3 daily meals, as measured by the change in hemoglobin A1c (HbA1c), from baseline to study week 24.
- Trial name
- NCT00135083
- Testing
- insulin glulisine
- Volunteers
- 347 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist
Primary Objective: To demonstrate the noninferiority in the efficacy of Toujeo® to Tresiba® in glycated hemoglobin (HbA1c) change from Baseline to Week 24.
- Trial name
- BRIGHT (NCT02738151)
- Testing
- Insulin glargine, 300U/mL, Insulin degludec, 100 U/mL, Non-insulin anti-diabetic treatment
- Where
- 158 sites in United States, Bulgaria and 14 more
- Volunteers
- 929 people
- Sponsor
- Sanofi
Diabetes, Type 2
The Inova Type 2 Diabetes Mellitus Study
The purpose of this study is to compare the safety and effectiveness of the two different basal insulins commonly used for basal blood sugar control in the treatment of type 2 diabetes mellitus in patients who are hospitalized…
- Trial name
- InovaDM2 (NCT02222623)
- Testing
- Glargine, NPH
- Where
- United States
- Sponsor
- Inova Health Care Services
Type 2 Diabetes Mellitus
A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)
This trial will assess the safety and efficacy of omarigliptin (MK-3102) compared with the sulfonylurea, glimepiride, in Type 2 diabetes mellitus participants with inadequate glycemic control on metformin monotherapy.
- Trial name
- NCT01682759
- Testing
- Omarigliptin, Glimepiride, Metformin
- Volunteers
- 751 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes
Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes
This is a 26-week randomized, open-label, multicenter, active-controlled parallel group trial. The purpose of this study is to compare efficacy and safety of THDB0206 injection with insulin lispro injection combined with insulin…
- Trial name
- NCT07282054
- Testing
- THDB0206, Insulin Lispro, Insulin Glargine
- Where
- China
- Volunteers
- 550 people
- Sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd
Diabetes Mellitus, Type 2
The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians
The overall objective of this study is to compare the effects of Soliqua, a titratable combination of insulin and GLP-1 receptor agonist in a single pen versus Glargine U100 insulin (Basaglar or Lantus) and gliclazide MR, both…
- Trial name
- VARIATION 2 SA (NCT03819790)
- Testing
- Basal insulin glargine and lixisenatide, Basal insulin Basaglar/Lantus + gliclazide MR, Metformin
- Where
- 3 sites in Canada
- Volunteers
- 119 people
- Sponsor
- LMC Diabetes & Endocrinology Ltd.
Diabetes Mellitus, Type 2
Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.
Primary Objective: >To obtain an estimation for both treatment groups of the proportion of patients that reach the target of HbA1c <= 7% without confirmed nocturnal hypoglycaemia in each treatment group.
- Trial name
- DINAMO (NCT01122979)
- Testing
- INSULIN GLARGINE, NPH insulin (insulin isophane), INSULIN GLULISINE
- Where
- 10 sites in Brazil
- Volunteers
- 72 people
- Sponsor
- Sanofi
Type 2 Diabetes, Hyperglycemia
Effect of Glargine Insulin on Glucose Control in Hospitalized Patients Who Receive Tube Feedings
The purpose of this study is to determine if the early initiation of a long acting insulin (i.e. glargine) with supplemental doses of short acting regular (SSR) insulin in hospitalized patients with diabetes who are fed using…
- Trial name
- NCT00177398
- Testing
- Glargine insulin vs regular insulin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Pittsburgh
Diabetes Mellitus, Type 1
Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis
The objective is to describe the interaction of equal doses of NPH insulin (Neutral Protamine Hagedorn), insulin Detemir and insulin glargine on IGFBP-1 (Insulin-like Growth Factor Binding Protein-1) production as well as…
- Trial name
- NCT01461616
- Testing
- NPH, Detemir, Glargine
- Where
- Denmark
- Volunteers
- 19 people
- Sponsor
- University of Aarhus
Type 2 Diabetes Mellitus
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)
Primary Objective: To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with type 2 diabetes mellitus (T2DM) inadequately…
- Trial name
- AMPLITUDE-L (NCT03713684)
- Testing
- Efpeglenatide SAR439977, Background therapy
- Where
- 47 sites in United States, China and 1 more
- Volunteers
- 370 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes
This study has 2 parts. Each participant will receive a daily injection of LY2605541 during one treatment period and a daily injection of insulin glargine during one treatment period.
- Trial name
- NCT01769404
- Testing
- LY2605541, Insulin Glargine
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company
Hyperglycemia Steroid-induced, Insulin Resistance, Diabetes
Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia
Glucocorticoids are known to cause an increase in insulin resistance, leading to hyperglycemia, in both diabetic and non-diabetic patients.
- Trial name
- NCT03511521
- Testing
- NPH Insulin, glargine, Insulin Aspart
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Northwestern University